

MSU 4.1-458  
Appl. No. 09/513,086  
October 11, 2005  
Reply to Office action of July 11, 2005

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS**

Claims 1-3 (Cancelled).

4. (Currently Amended): A composition consisting of comprising an isolated a single naturally occurring 16 ( $\pm 4$ ) kDa protein antigen isolated from Sarcocystis neurona antigen and an isolated a single naturally occurring 30 ( $\pm 4$ ) kDa protein antigen isolated from Sarcocystis neurona antigen in a pharmaceutically accepted carrier.

Claims 5-12 (Cancelled).

13. (Currently Amended): A method for treating an equine with a *Sarcocystis neurona* infection comprising:

(a) providing a composition consisting essentially of ~~an isolated~~ of a single naturally occurring 16 ( $\pm 4$ ) kDa protein antigen isolated from *Sarcocystis* *neurona* and an isolated a single naturally occurring 30 ( $\pm 4$ ) kDa protein antigen isolated from ~~of~~ *Sarcocystis* *neurona* in a pharmaceutically accepted carrier; and

(b) inoculating the equine with the composition to treat the equine with the *Sarcocystis neurona* infection.

Claims 14-45. (Cancelled).

46. (Currently Amended): A method for treating a disease in an equine caused by a *Sarcocystis neurona* infection which comprises providing a composition which when injected into the equine causes the equine to produce antibodies against a 16 ( $\pm 4$ ) kDa antigen and a 30 ( $\pm 4$ ) kDa antigen of the *Sarcocystis neurona* which treats the disease caused by the *Sarcocystis neurona*, The method of Claim 45 wherein the composition consists of comprises an isolated a single naturally occurring 16 ( $\pm 4$ ) kDa protein antigen isolated from *Sarcocystis neurona* and an isolated a single naturally occurring 30 ( $\pm 4$ ) kDa protein antigen isolated from *Sarcocystis neurona* in a pharmaceutically accepted carrier.

Claims 47-49 (Cancelled).

50. (Currently Amended): The method of Claim 46 45 wherein the composition is administered by an inoculation route selected from the group consisting of intranasal administration, intramuscular injection, intraperitoneal injection, intradermal injection, and subcutaneous injection.